Decisions of Herantis Pharma Plc’s Extraordinary General Meeting of Shareholders

Herantis Pharma Plc
Company release 12 Mar 2019 at 3:00 pm

Decisions of Herantis Pharma Plc’s Extraordinary General Meeting of Shareholders

Herantis Pharma Plc
Company release 12 March 2019 at 3:00 PM

An Extraordinary General Meeting of Shareholders of Herantis Pharma Plc (“Herantis” or “Company”) was held in Helsinki on Tuesday, 12 March 2019.

Matters that were on the agenda of the Extraordinary General Meeting of Shareholders

The Extraordinary General Meeting of Shareholders resolved, as proposed by the Board of Directors, to increase the number of the members of the Board of Directors of the Company from five (5) to six (6) and to elect Ingrid Atteryd Heiman as a new member of the Board of Directors.

The Extraordinary General Meeting of Shareholders resolved to authorize the Board of Directors, as proposed by the Board of Directors, to decide on the issuance of shares as follows:

The shares issued under the authorization may be new shares or treasury shares. Under the authorization, a maximum of 1,500,000 shares, which corresponds to approximately 30.5 percent of all of the shares in the Company, may be issued. The shares may be issued in one or more tranches.

Under the authorization, shares may be issued for the purposes of financing the development necessary for the business of the Company such as activities related to preparations for the Phase 2 and Phase 3 clinical studies of CDNF and Lymfactin, preclinical development of a non-invasive CDNF, strengthening the Company’s capital structure, as well as for other purposes decided by the Board of Directors.

Under the authorization, shares may also be issued, among others, to the members of the Board of Directors, the CEO or the employees of the Company. Under the authorization, the Board of Directors may resolve upon issuing new shares to the Company itself. However, the Company, together with its subsidiaries, may not at any time hold more than 10 percent of all its registered shares.

The Board of Directors is authorized to resolve on all terms of the share issue. The Board of Directors is authorized to resolve on a directed share issue in deviation from the shareholders’ pre-emptive rights, provided that there is a weighty financial reason for the Company to do so.

The proposed authorization does not invalidate any earlier authorizations entitling the Board of Directors to decide on share issues or issues of special rights entitling to shares.

The authorization is valid for five (5) years from the decision of the Extraordinary General Meeting of Shareholders.

HERANTIS PHARMA PLC

Further information:
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:
Nasdaq Helsinki
Main media
www.herantis.com